Experience in production of (68)Ga-DOTA-NOC for clinical use under an Expanded Access IND

Experience in production of (68)Ga-DOTA-NOC for clinical use under an Expanded Access IND

[(68)Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert & Ziegler (EZAG) (68)Ge/(68)Ga-generator (with fractionated elution), or the SiO2-based ITG (68)Ge/(68)G...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Applied radiation and isotopes 2016-10, Vol.116, p.63-68
Hauptverfasser: Green, Mark A, Mathias, Carla J, Fletcher, James W
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 68
container_issue
container_start_page 63
container_title Applied radiation and isotopes
container_volume 116
creator Green, Mark A
Mathias, Carla J
Fletcher, James W
description [(68)Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert & Ziegler (EZAG) (68)Ge/(68)Ga-generator (with fractionated elution), or the SiO2-based ITG (68)Ge/(68)Ga-generator. In both cases, [(68)Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the(68)Ga generator eluate, using readily-implemented manual synthesis procedures. [(68)Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered (68)Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2µg (n=47) and 23.9±5.7µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, (68)Ge breakthrough in the final product averaged 2.7×10(-7)% and 5.4×10(-5%) using the EZAG and ITG generators, respectively.
doi_str_mv 10.1016/j.apradiso.2016.07.010
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1819430553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1819430553</sourcerecordid><originalsourceid>FETCH-LOGICAL-p196t-d9ef9171300681d04ea00730da7b1464282d2f1f1b1a84dd5faaf18f0f221a713</originalsourceid><addsrcrecordid>eNo1UE1rwkAUXAqlWtu_IHu0h6Tvbb42R1FrBTEXe-gpPPcDVuImzRpo_30DtaeZgZlhGMbmCDEC5q_nmLqetAttLEYdQxEDwh2boixEVEqACXsM4QwAqSzFA5uIIgPEJJ-yz813Z3pnvDLced71rR7U1bWet5YvcvmypWhdHZfRoVpx2_ZcNc47RQ0fguGD16bn5PnYQiPXfKmUCYHvDusndm-pCeb5hjP28bY5rt6jfbXdrZb7qMMyv0a6NLbEAhOAXKKG1BBAkYCm4oRpngoptLBo8YQkU60zS2RRWrBCII25GVv89Y7bvwYTrvXFBWWahrxph1CjxDJNIMuS0Tq_WYfTxei6692F-p_6_47kF3l1X9I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1819430553</pqid></control><display><type>article</type><title>Experience in production of (68)Ga-DOTA-NOC for clinical use under an Expanded Access IND</title><source>Elsevier ScienceDirect Journals</source><creator>Green, Mark A ; Mathias, Carla J ; Fletcher, James W</creator><creatorcontrib>Green, Mark A ; Mathias, Carla J ; Fletcher, James W</creatorcontrib><description>[(68)Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert &amp; Ziegler (EZAG) (68)Ge/(68)Ga-generator (with fractionated elution), or the SiO2-based ITG (68)Ge/(68)Ga-generator. In both cases, [(68)Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the(68)Ga generator eluate, using readily-implemented manual synthesis procedures. [(68)Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered (68)Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2µg (n=47) and 23.9±5.7µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, (68)Ge breakthrough in the final product averaged 2.7×10(-7)% and 5.4×10(-5%) using the EZAG and ITG generators, respectively.</description><identifier>EISSN: 1872-9800</identifier><identifier>DOI: 10.1016/j.apradiso.2016.07.010</identifier><identifier>PMID: 27501136</identifier><language>eng</language><publisher>England</publisher><ispartof>Applied radiation and isotopes, 2016-10, Vol.116, p.63-68</ispartof><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27501136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Green, Mark A</creatorcontrib><creatorcontrib>Mathias, Carla J</creatorcontrib><creatorcontrib>Fletcher, James W</creatorcontrib><title>Experience in production of (68)Ga-DOTA-NOC for clinical use under an Expanded Access IND</title><title>Applied radiation and isotopes</title><addtitle>Appl Radiat Isot</addtitle><description>[(68)Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert &amp; Ziegler (EZAG) (68)Ge/(68)Ga-generator (with fractionated elution), or the SiO2-based ITG (68)Ge/(68)Ga-generator. In both cases, [(68)Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the(68)Ga generator eluate, using readily-implemented manual synthesis procedures. [(68)Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered (68)Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2µg (n=47) and 23.9±5.7µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, (68)Ge breakthrough in the final product averaged 2.7×10(-7)% and 5.4×10(-5%) using the EZAG and ITG generators, respectively.</description><issn>1872-9800</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo1UE1rwkAUXAqlWtu_IHu0h6Tvbb42R1FrBTEXe-gpPPcDVuImzRpo_30DtaeZgZlhGMbmCDEC5q_nmLqetAttLEYdQxEDwh2boixEVEqACXsM4QwAqSzFA5uIIgPEJJ-yz813Z3pnvDLced71rR7U1bWet5YvcvmypWhdHZfRoVpx2_ZcNc47RQ0fguGD16bn5PnYQiPXfKmUCYHvDusndm-pCeb5hjP28bY5rt6jfbXdrZb7qMMyv0a6NLbEAhOAXKKG1BBAkYCm4oRpngoptLBo8YQkU60zS2RRWrBCII25GVv89Y7bvwYTrvXFBWWahrxph1CjxDJNIMuS0Tq_WYfTxei6692F-p_6_47kF3l1X9I</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Green, Mark A</creator><creator>Mathias, Carla J</creator><creator>Fletcher, James W</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201610</creationdate><title>Experience in production of (68)Ga-DOTA-NOC for clinical use under an Expanded Access IND</title><author>Green, Mark A ; Mathias, Carla J ; Fletcher, James W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p196t-d9ef9171300681d04ea00730da7b1464282d2f1f1b1a84dd5faaf18f0f221a713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Green, Mark A</creatorcontrib><creatorcontrib>Mathias, Carla J</creatorcontrib><creatorcontrib>Fletcher, James W</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Applied radiation and isotopes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Green, Mark A</au><au>Mathias, Carla J</au><au>Fletcher, James W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experience in production of (68)Ga-DOTA-NOC for clinical use under an Expanded Access IND</atitle><jtitle>Applied radiation and isotopes</jtitle><addtitle>Appl Radiat Isot</addtitle><date>2016-10</date><risdate>2016</risdate><volume>116</volume><spage>63</spage><epage>68</epage><pages>63-68</pages><eissn>1872-9800</eissn><abstract>[(68)Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert &amp; Ziegler (EZAG) (68)Ge/(68)Ga-generator (with fractionated elution), or the SiO2-based ITG (68)Ge/(68)Ga-generator. In both cases, [(68)Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the(68)Ga generator eluate, using readily-implemented manual synthesis procedures. [(68)Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered (68)Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2µg (n=47) and 23.9±5.7µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, (68)Ge breakthrough in the final product averaged 2.7×10(-7)% and 5.4×10(-5%) using the EZAG and ITG generators, respectively.</abstract><cop>England</cop><pmid>27501136</pmid><doi>10.1016/j.apradiso.2016.07.010</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1872-9800
ispartof Applied radiation and isotopes, 2016-10, Vol.116, p.63-68
issn 1872-9800
language eng
recordid cdi_proquest_miscellaneous_1819430553
source Elsevier ScienceDirect Journals
title Experience in production of (68)Ga-DOTA-NOC for clinical use under an Expanded Access IND
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T03%3A47%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experience%20in%20production%20of%20(68)Ga-DOTA-NOC%20for%20clinical%20use%20under%20an%20Expanded%20Access%20IND&rft.jtitle=Applied%20radiation%20and%20isotopes&rft.au=Green,%20Mark%20A&rft.date=2016-10&rft.volume=116&rft.spage=63&rft.epage=68&rft.pages=63-68&rft.eissn=1872-9800&rft_id=info:doi/10.1016/j.apradiso.2016.07.010&rft_dat=%3Cproquest_pubme%3E1819430553%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1819430553&rft_id=info:pmid/27501136&rfr_iscdi=true